1Desmond RA,Soong SJ.Epidemiology of malignant melanoma[J].Surg Clin North Am,2003,83:1-29. 被引量：1
2Atkins MB,Buzaid AC,Houghton AN Jr.Chemotherapy and biochemotherapy[M].In:Balch C,Houghton A,Sober A,Soong S,eds.Cutaneous melanoma.4th ed.St.Louis:Quality Medical Publishing,2003:589-604. 被引量：1
3Lens MB,Dawes M.Interferon alfa therapy for malignant melanoma:a systematic review of randomized controlled trials[J].J Clin Oncol,2002,20:1818-25. 被引量：1
4Cameron DA,Cornbleet MC,Mackie RM,et al.Adjuvant interferon alpha 2b in high risk melanoma:the Scottish study[J].Br J Cancer,2001,84:1146-1149. 被引量：1
5UR Kleeberg,S Suciu,EB Brocker,et al.Final results of the EORTC 18871/DKG 80-1 randomised phase Ⅲ trial.rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness＞3mm)or regional lymph node metastasis[J].Eur J Cancer,2004,40(3):390-402. 被引量：1
6Hancock BW,Wheatly K,Harrison G,et al.Aim high:adjuvant interferon in melanoma(high risk),a United Kingdom Co-ordinating Committee on Cancer Research(UKCCCR)randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma[J].Proc Am Soc Clin Oncol,2001,20:349a(abstr 1393). 被引量：1
7Eggermont AMM,Kleeberg UR,Ruiter DJ,et al.The European Organization for Research and Treatment of Cancer Melanoma Group Trial Experience with more than 2,000 patients,evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b[M].In:Perry MC,ed.American Society of Clinical Oncology 2001 Educational Book.Alexandria,VA,USA 2001:88-93. 被引量：1
8Eggermont A M M,Punt C J A Does Adjuvant Systemic Therapy with Interferon-alpha for Stage Ⅱ-Ⅲ Melanoma Prolong Survival[J]?American Journal of Clinical Dermatology,2003,4(8):531-536. 被引量：1
9Kirkwood JM,Strawderman MH,Ernstoff MC,et al.Interferon alfa-2b adjuvant therapy of highrisk resected cutaneous melanoma:the Eastern Cooperative Oncology Group trial EST 1684[J].J Clin Oncol,1996,14:7-17. 被引量：1
10Sanjiv SA,Kirkwood JM.Update on the role of adjuvant interferon for high risk melanoma[J].Forum,2000,10:230-239. 被引量：1
2Desmond RA,Soong SJ. Epidemiology of malignant melanoma[J]. Surg Clin North Am,2003 ,83 ( 1 ) : 1 - 29. 被引量：1
3Atkins MB, Buzaid AC, Houghton AN Jr. Chemotherapy and biochemotherapy[ A]. In : Balch C, Houghton A, Sober A, eds. Cutaneous melanoma [ M ]. St. Louis: Quality Medical Publishing, 2003:589. 被引量：1
4Mcguire WP, Blessing JA, Bookman MA, et al. Adjuvant therapy of melanoma patiens( stage Ⅱ ,Ⅲ) : a pilot immuno - toxicological study [J]. Exp Clin Cancer Res,2004,23(4) :573 -578. 被引量：1
5Grimm EA, Staid CM, Lee JJ, et al. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy [J]. Clin Cancer Res,2000,6(10) :3895 -903. 被引量：1
6John M, Kirkwood, Stergios Moschos, et al. Strategies for the development of more effective adjuvant therapy of melanoma : Current and future explorations of antibodies, cytokines, vaccines, and combinations [J]. Clin Cancer Res, 2006,12 ( 15 ) : 2331 - 2336. 被引量：1
7Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma:a systematic review of randomized controlled trials [ J]. J Clin Oncol,2002,20(7 ) : 1818 - 1825. 被引量：1
8Michael B, Atkins. Cytokine - based therapy and biochemotherapy for advanced melanoma[J]. Clin Caner Res,2006,12 (7) ,2353 - 2358. 被引量：1
9Kilbridge KL, Weeks JC, Sober A J, et al. Patient preferences for adjuvant interferon alfa- 2 b treatment [ J]. J Clin Oncol,2001,19 (16) :812 - 823. 被引量：1
10P Lindner, M Rizell, J Mattsson, et al. Combined treatment with histamine dihydrochloride, interleukin - 2 and interferon - alpha in patients with metastatic melanoma [J].Anticancer Res, 2004, 24(36) :1837 - 1842. 被引量：1
